These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16282296)

  • 1. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
    Wasunna MK; Rashid JR; Mbui J; Kirigi G; Kinoti D; Lodenyo H; Felton JM; Sabin AJ; Albert MJ; Horton J
    Am J Trop Med Hyg; 2005 Nov; 73(5):871-6. PubMed ID: 16282296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
    Jha TK; Sundar S; Thakur CP; Felton JM; Sabin AJ; Horton J
    Am J Trop Med Hyg; 2005 Dec; 73(6):1005-11. PubMed ID: 16354802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
    Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
    Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
    Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
    Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.
    Dietze R; Carvalho SF; Valli LC; Berman J; Brewer T; Milhous W; Sanchez J; Schuster B; Grogl M
    Am J Trop Med Hyg; 2001 Dec; 65(6):685-9. PubMed ID: 11791957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
    Sundar S; Chakravarty J; Rai VK; Agrawal N; Singh SP; Chauhan V; Murray HW
    Clin Infect Dis; 2007 Sep; 45(5):556-61. PubMed ID: 17682988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani.
    Bories C; Cojean S; Huteau F; Loiseau PM
    Biomed Pharmacother; 2008 Mar; 62(3):164-7. PubMed ID: 18249083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.
    Singh UK; Prasad R; Jaiswal BP; Singh PK; Thakur CP
    J Trop Pediatr; 2010 Oct; 56(5):321-4. PubMed ID: 20065047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.
    Bhattacharya SK; Jha TK; Sundar S; Thakur CP; Engel J; Sindermann H; Junge K; Karbwang J; Bryceson AD; Berman JD
    Clin Infect Dis; 2004 Jan; 38(2):217-21. PubMed ID: 14699453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis.
    Sherwood JA; Gachihi GS; Muigai RK; Skillman DR; Mugo M; Rashid JR; Wasunna KM; Were JB; Kasili SK; Mbugua JM
    Clin Infect Dis; 1994 Dec; 19(6):1034-9. PubMed ID: 7888530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes.
    Dueñas-Romero AM; Loiseau PM; Saint-Pierre-Chazalet M
    Biochim Biophys Acta; 2007 Feb; 1768(2):246-52. PubMed ID: 16945323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
    Jha TK; Sundar S; Thakur CP; Bachmann P; Karbwang J; Fischer C; Voss A; Berman J
    N Engl J Med; 1999 Dec; 341(24):1795-800. PubMed ID: 10588964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
    Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
    Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
    J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.
    Sundar S; Singh A; Rai M; Prajapati VK; Singh AK; Ostyn B; Boelaert M; Dujardin JC; Chakravarty J
    Clin Infect Dis; 2012 Aug; 55(4):543-50. PubMed ID: 22573856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.